Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.63 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15716777 | 0.96 | NR1H2 (0.59) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL31520532 | 0.81 | ADORA3 (0.50) | NR1H2NR1H3NPC1RAB9AKMT2A | |
| SCHEMBL822566 | 0.78 | NR1H3 (1.00) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL16202035 | 0.78 | NR1H3 (0.71) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL29422230 | 0.77 | KMT2A (0.42) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL14554797 | 0.76 | NR1H3 (0.63) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL11333361 | 0.76 | NR1H3 (0.63) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL11172407 | 0.76 | NR1H3 (0.63) | NR1H2NR1H3NPC1RAB9AGAA | |
| SCHEMBL28122847 | 0.74 | NR1H3 (0.70) | NR1H2NR1H3NPC1RAB9AALDH1A1 | |
| SCHEMBL21301566 | 0.73 | NR1H3 (0.59) | NR1H2NR1H3NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466182-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED | 2012-02-23 | — | — | US | disclosed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420494-A1 | Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071631-B2 | An enzyme in the tryptophan degradation pathway, used to treat neurodegenerative disorders, certain cancers, drug addiction; arylsulfonamides such as 3,4-dimethoxy-N-[5-(4-chlorophenyl)-1,2,4-thiadiazole-3-yl]benzenesulfonamide | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2054056-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | J. DAVID GLADSTONE INSTITUTES | 2008-03-20 | — | — | US | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008022286-A2 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2008-02-21 | — | — | WO | disclosed |
| US-4536508-A | ANTIALLERGENS AND ANTIINFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 1985-08-20 | — | — | US | disclosed |
| EP-0016565-B1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-05-23 | — | — | EP | disclosed |
| EP-0016565-A1 | 1,2,4-Triazole derivatives, processes for their production and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070937-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | NR1H2 1211/4885NR1H3 1109/4885NPC1 3651/4885 |
| US-20120046324-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | NR1H2 1211/4885NR1H3 1109/4885NPC1 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.